Controlled release and taste masking oral pharmaceutical composition
DC CAFCFirst Claim
1. A tablet for the treatment of ulcerative colitis consisting essentially of (1) a tableted core, and (2) a coating on said tableted core, wherein said tableted core consists of a matrix comprising:
- (a) 9 mg of budesonide;
(b) hydroxypropyl methylcellulose; and
(c) magnesium stearate;
wherein said coating on said tableted core comprises methacrylic acid copolymer type A, methacrylic acid copolymer type B, or a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B;
wherein following oral administration of the tablet to a human, the tablet provides an AUC of said budesonide in said human of about 16.43±
10.52 (ng)×
(h)/mL;
and wherein said tablet provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human.
2 Assignments
Litigations
0 Petitions
Accused Products
Abstract
Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.
69 Citations
30 Claims
-
1. A tablet for the treatment of ulcerative colitis consisting essentially of (1) a tableted core, and (2) a coating on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl methylcellulose; and (c) magnesium stearate; wherein said coating on said tableted core comprises methacrylic acid copolymer type A, methacrylic acid copolymer type B, or a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B; wherein following oral administration of the tablet to a human, the tablet provides an AUC of said budesonide in said human of about 16.43±
10.52 (ng)×
(h)/mL;and wherein said tablet provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)
-
-
26. A tablet consisting essentially of (1) a tableted core, and (2) a gastro-resistant coating on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl methylcellulose; (c) magnesium stearate; (d) hydroxypropyl cellulose; (e) silicon dioxide; (f) lactose; (g) starch or a starch derivative; (h) microcrystalline cellulose; and (i) lecithin; wherein said gastro-resistant coating comprises methacrylic acid copolymer type A, methacrylic acid copolymer type B and triethylcitrate; wherein following oral administration of the tablet to a human, the tablet provides an AUC of said budesonide in said human of about 16.43±
10.52 (ng)×
(h)/mL;and wherein said tablet provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human. - View Dependent Claims (27, 28)
-
-
29. A tablet consisting essentially of (1) a tableted core, and (2) a gastro-resistant coating on said tableted core, wherein said tableted core consists of a matrix comprising:
-
(a) 9 mg of budesonide; (b) hydroxypropyl cellulose; and (c) magnesium stearate; wherein said coating on said tableted core comprises methacrylic acid copolymer type A, methacrylic acid copolymer type B, or a mixture of methacrylic acid copolymer type A and methacrylic acid copolymer type B; wherein following oral administration of the tablet to a human, the tablet provides an AUC of said budesonide in said human of about 16.43±
10.52 (ng)×
(h)/mL, a Cmax of said budesonide in said human of about 1.35±
0.96 ng/mL, and a Tmax of said budesonide in said human of about 13.3±
5.9 hour,and wherein said tablet provides extended release of budesonide in the colon of said human effective to treat ulcerative colitis in said human. - View Dependent Claims (30)
-
Specification